Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Cephalon Makes an Offer For Arana
by Ann M. Thayer
March 9, 2009
| A version of this story appeared in
Volume 87, Issue 10
Cephalon has made a $207 million offer to acquire the 80% of Australia’s Arana Therapeutics that it does not already own. Arana develops antibody-based drugs to treat inflammatory diseases and cancer. Its lead candidate, a tumor necrosis factor alpha blocker, is in Phase II trials for both psoriasis and rheumatoid arthritis. The company also receives royalties from Abbott Laboratories and Johnson & Johnson for technology licenses. Arana’s independent directors are recommending that shareholders accept the deal in the absence of a better proposal.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X